News

Article

Teva Proposes $40 Billion to Acquire Mylan

Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.

 

Teva announced a proposal on April 21, 2015 to acquire Mylan for $40 billion, or $82 per share, in cash and stocks. According to a press release, the combined company would focus on complex technologies, more durable and sustainable products, and enhanced capabilities in specialty drug development and commercialization.

“We have long respected Mylan’s business, and we are confident that Mylan’s Board of Directors and stockholders will agree that our proposal represents a significantly more attractive alternative for Mylan and its stockholders than Mylan’s proposed acquisition of Perrigo,” said Erez Vigodman, president and CEO of Teva, in a press release.

This proposal comes a mere two weeks after Mylan proposed $29 billion to acquire Perrigo. The deal could have been a defensive move by Mylan, because Teva was already interested in acquiring Mylan, according to the New York Times. The Times continues by mentioning that Mylan’s executive chairman, Robert J. Coury, was quoted as saying earlier in the month that Mylan is committed to the Perrigo deal and is uninterested in an acquisition by Teva. 

Source: Teva

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content